Inhalative long-term sedation with sevoflurane/remifentanil using the AnaConDa® system

Efficiency and safety of inhalative long-term sedation with sevoflurane/remifentanil compared to intravenous sedation with propofol/remifentanil in intensive care patients: a prospective randomised clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN90609144

Enrollment

100

Registered

2008-07-31

Start date

2009-01-08

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation Signs and Symptoms Sedation

Interventions

Sedation using the AnaConDa® system. The study protocol implies a randomised prospective study with two groups including 50 patients in each group. Group S will be sedated with sevofl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged older than 18 years, either sex 2. Critically ill patients with mechanical ventilation 3. Need analgosedation for more than 48 hours

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Primary unfavourable prognosis

Design outcomes

Primary

Measure	Time frame
Weaning time (time end of sedation until spontaneous breathing)	—

Secondary

Measure	Time frame
1. Sedation quality (daily assessment, Richmond Agitation Sedation scale, relation between aspired to real sedation depth, frequency of additional boli) 2. Flouride (daily measurement up to 3 days after stop sedation) 3. Cardiac markers (daily measurement up to 3 days after stop sedation) 4. Sedation depth (daily assessment, Richmond Agitation Aedation scale, BIS-Monitoring)	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 25, 2026